Till startsida
To content Read more about how we use cookies on gu.se

Group Göran Landberg

Research summary

Breast cancer consists of a multitude of different diseases with varying behaviours and it is critical to identify subgroups with similar tumour biological properties as well as define groups that will respond to specific treatments.

Within the project we have pinpointed several alterations in breast cancer that are associated with an impaired response to endocrine treatment. In the quest to understand how proliferation and migration are regulated and potential common regulatory pathways we have also obtained completely novel information about coordinated but contrasting regulation of key tumour properties in ER-positive and ER-negative breast cancer.

These two main themes within the laboratory will now be further challenged by adding the complexity of the tumour microenvironment as well as the presence of cancer stem cells. We will focus on our findings suggesting that breast cancer will respond differently to low oxygen and we will detail the mechanism behind this contrasting behaviour as well as identify key regulators mediating the obvious increase of cancer stem cells in some tumours during hypoxia.

Ultimately we will identify novel inhibitors that block this process and potentially launch a therapy approach for increasing the efficiency of hypoxia or anti-angiogenic therapies or alternatively, identify markers for when hypoxia-induced therapy will be beneficial or not. The projects are currently carried out in Sweden and in England.

Research tools and resources

We provide an integrated approach for breast cancer research by combining the analysis of clinical observations in vivo with cell and molecular techniques in the laboratory. We also construct and analyse large sets of primary tumour materials in tissue microarrays (TMAs) linked to clinical data bases.

Current group members

Göran Landberg, MD, PhD, Professor
Andreas Svanström, PhD, Post doc
Maria del Carmen Leiva Arrabad, Post doc
Sara Rhost, Post doc
Anna Gustafsson, PhD student
Karoline Berger, PhD student
Emma Persson, PhD student
Pernilla Gregersson, Technician, Lab manager
Elena Garre, Researcher
Simona Salerno, Researcher

Recent selected publications

  1. Identification of Breast Cancer Stem Cell Related Genes Using Functional Cellular Assays Combined With Single-Cell RNA Sequencing in MDA-MB-231 Cells.
    Jonasson E, Ghannoum S, Persson E, Karlsson J, Kroneis T, Larsson E, Landberg G, Ståhlberg A. Front Genet. 2019, May 22
  2. Hypoxia-induced secretion stimulates breast cancer stem cell regulatory signalling pathways.
    Jacobsson H, Harrison H, Hughes É, Persson E, Rhost S, Fitzpatrick P, Gustafsson A, Andersson D, Gregersson P, Magnusson Y, Ståhlberg A, Landberg G. Mol Oncol. 2019, Aug 13
  3. JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma.
    Dolatabadi S, Jonasson E, Lindén M, Fereydouni B, Bäcksten K, Nilsson M, Martner A, Forootan A, Fagman H, Landberg G, Åman P, Ståhlberg A. Int J Cancer. 2019 Jul 15
  4. Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion.
    Rhost S, Hughes É, Harrison H, Rafnsdottir S, Jacobsson H, Gregersson P, Magnusson Y, Fitzpatrick P, Andersson D, Berger K, Ståhlberg A, Landberg G. Breast Cancer Res. 2018 Nov 20
  5. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.
    Svec D, Dolatabadi S, Thomsen C, Cordes N, Shannon M, Fitzpatrick P, Landberg G, Åman P, Ståhlberg A. Lab Invest. 2018 Jul
  6. Cellular organization and molecular differentiation model of breast cancer-associated fibroblasts.
    Busch S, Andersson D, Bom E, Walsh C, Ståhlberg A, Landberg G. Mol Cancer. 2017 Apr 3
  7. Cell Cycle and Cell Size Dependent Gene Expression Reveals Distinct Subpopulations at Single-Cell Level.
    Dolatabadi S, Candia J, Akrap N, Vannas C, Tesan Tomic T, Losert W, Landberg G, Åman P, Ståhlberg A. Front Genet. 2017 Jan 25
  8. High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer.
    Paulsson J, Rydén L, Strell C, Frings O, Tobin NP, Fornander T, Bergh J, Landberg G, Stål O, Östman A. J Pathol Clin Res. 2016 Sep 14
  9. Tissue Factor promotes breast cancer stem cell activity in vitro.
    Shaker H, Harrison H, Clarke R, Landberg G, Bundred NJ, Versteeg HH, Kirwan CC. Oncotarget. 2017 Apr 18
  10. Lipid Heterogeneity Resulting from Fatty Acid Processing in the Human Breast Cancer Microenvironment Identified by GCIB-ToF-SIMS Imaging.
    Angerer TB, Magnusson Y, Landberg G, Fletcher JS. Anal Chem. 2016 Dec 6

More group Göran Landberg publications on PubMed

Contact information

Göran Landberg

E-mail: Göran Landberg
Phone: +46 (0)31 786 6736

Visiting address:
Sahlgrenska Center
for Cancer Research,
Medicinaregatan 1F
413 90 Gothenburg

Page Manager: Yael Zukovsky Fitoussi|Last update: 11/15/2019

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?